NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Vistagen Therapeutics, Inc. VTGN
19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-69.7M
Growth
USD 1.3M
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 1.3 · Net income -69.7
Compound annual growth
Revenue compounded at +3.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−5491 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -5683.7% · Net -5491.3%
ROE
FY2025 · ROE -131.6%
Each USD of equity lost 132 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | 0.0 | 0.0 | 0.0 | · | · | · |
| Operating income $B | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | −0.1 | −0.1 | −0.0 | −0.1 | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Net income $B | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · | · | · | · |
| EPS, diluted $ | −1.83 | −1.67 | −1.52 | −8.51 | · | −0.49 | −0.50 | −0.90 | −1.12 | −1.54 | −29.08 | −10.61 | −3.81 | −1.27 | −0.83 | −1.81 | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −131.6 | −55.7 | −46.5 | −154.3 | −61.0 | −41.6 | −3087.2 | −351.5 | −380.9 | · | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 67 reconciliationsAUDITED
Reconciled in 18 of 19 fiscal years. 9 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2007